Results 131 to 140 of about 692,269 (276)

Structure-Based Design of Novel Inhibitors of the MDM2–p53 Interaction

, 2016
Structure-based rational design led to the discovery of novel inhibitors of the MDM2–p53 protein–protein interaction. The affinity of these compounds for MDM2 was improved through conformational control of both the piperidinone ring and the appended N ...
Felix Gonzalez-Lopez De Turiso (1840651), Frank Kayser (1570123), Steven H. Olson (1570108), Xuelei Yan (1698157), Jeffrey Deignan (1840639), Xiaoning Zhao (184301), Michael D. Bartberger (1261599), Yihong Li (105659), Steve Schneider (1864738), Mei-Chu Lo (1698175), Jonathan D. Oliner (1698163), Peter Yakowec (1698136), Hilary P. Beck (1570117), Brian M. Fox (1828315), Qiuping Ye (1698148), Mark Ragains (2074054), Yosup Rew (1698184), Xin Huang (11077), Anne Y. Saiki (1765267), Maria Toteva (133167), Min Jiang (56794), Xianyun Jiao (1706488), Dongyin Yu (1698181), Julio C. Medina (1692928), Darin Gustin (431192), Jude Canon (1698172), Alexander M. Long (1840645), Jing Zhou (168494), Daqing Sun (1698151), Lixia Jin (1570120), David J. Kopecky (2074051), Ada Chen (1698127), David Chow (300976), Klaus Michelsen (1261590), Tao Osgood (1698133)   +34 more
core   +1 more source

Dihydroartemisinin Engages NQO1 and Promotes Ferroptosis‐Related Oxidative Stress in Non‐Small Cell Lung Cancer

Phytotherapy Research, EarlyView.
Dihydroartemisinin Engages NQO1 and Promotes Ferroptosis‐Related Oxidative Stress in Non‐Small Cell Lung Cancer. ABSTRACT Dihydroartemisinin (DHA), a bioactive derivative of Artemisia annua L. (AAL), has shown antitumor activity in several malignancies, including non‐small cell lung cancer (NSCLC).
Xiuli Guo, Gan Tao, Mini Zhang, Linzhi Han, Sisi Yan, Chunsheng Wang, Jianguo Zhang, Xiaowan Guo, Kehua Hu, Yan Gong, Qiuji Wu, Conghua Xie   +11 more
wiley   +1 more source

Virtual screening of low molecular weight mushrooms compounds as potential Mdm2 inhibitors.

, 2013
In some human cancer cases, the activity of p53 is inhibited by overexpressed Mdm2. Mdm2 acts as an ubiquitin ligase, resulting in p53 ubiquitination and subsequent p53 proteasomal degradation.
Abreu, Rui M.V., Froufe, Hugo J.C., Ferreira, Isabel C.F.R.   +2 more
core   +1 more source

Stimuli‐responsive nanostructured hydrogen sulfide donors for enhanced cancer treatments

Smart Molecules, EarlyView.
Three typical kinds of stimuli‐responsive nanostructured hydrogen sulfide (H2S) donors are reviewed. The nanostructures ensure precise delivery of H2S to the lesion site and regulate the release behavior. The H2S‐based gas therapy has been used to synergize with other cancer treatment modalities, achieving enhanced efficacy while reducing side effects.
Yuxuan Lyu, Jiaxuan Zhu, Lei Lei, Qingyang Zhong, Zhao Li, Caihong Lei, Fan Rong, Yin Wang   +7 more
wiley   +1 more source

Enhanced 5-FU-mediated activation of p53-dependent nucleolar stress by MDM2/4 peptide inhibitors in colon cancer cells

, 2022
Recent evidence suggest that the p53-dependent nucleolar stress induced by some anticancer drugs, such as 5-Fluorouracil (5-FU), might not be sufficient to produce cell cycle arrest and/or apoptosis, given the hyperactivation of MDM2 and MDM4, main ...
Giulia Russo, Annalisa Pecoraro, Daniele Bravoco, Chiara Brignola, Annapina Russo., Francesco Merlino, Valeria La Pietra   +6 more
core  

Artificial intelligence empowers targeted protein degradation: Core technological innovations, multi‐scenario applications, and translational prospects

Smart Molecules, EarlyView.
AI is transforming TPD by improving the design, prediction, and optimization of degraders such as PROTACs, molecular glues, and LYTACs. This review summarizes key AI‐driven advances, highlights applications across drug discovery stages, and discusses remaining challenges and future directions for accelerating the development of therapies against ...
Shuanglin Qin, Rui Peng, Guangshuai Zhang, Si Yan, Jin Xiao, Zishu Liu, Ziyu Tan, Qingqing Xie, Shangjie Li, Wei Luo, Xiaohe Xiao   +10 more
wiley   +1 more source

LINC00892 inhibits hepatocellular carcinoma progression through SBDS/EIF6‐mediated ribosomal stress and interacting with the immune microenvironment

VIEW, EarlyView.
LINC00892 is lowly expressed in HCC. LINC00892 overexpression induces ribosomal stress via inhibiting SBDS, restrains EIF6 nuclear translocation and activates p53 pathway. LINC00892 overexpression and p53 activation jointly suppress HCC progression. High LINC00892 is associted with infiltration of CD8+ T cells, B cells and macrophages, and associated ...
Xu Zhang, Lina Ma, Juan Ma, Long Hai, Lina Wu, Xueyan Feng, Xiangchun Ding   +6 more
wiley   +1 more source

Supplementary Data from Interactions between MDM2 and TP53 Genetic Alterations, and Their Impact on Response to MDM2 Inhibitors and Other Chemotherapeutic Drugs in Cancer Cells

, 2009
Supplementary Data from Interactions between MDM2 and TP53 Genetic Alterations, and Their Impact on Response to MDM2 Inhibitors and Other Chemotherapeutic Drugs in Cancer ...
Wanqing Liu (25627), Jacqueline Ramírez (5651281), Mark J. Ratain (9872087), Lijun He (4040003)   +3 more
core   +1 more source

The Functional Role and Molecular Characterization of the Therapeutic Target CLDN6 in Germ Cell Tumors

Andrology, EarlyView.
ABSTRACT Background The tight junction protein CLDN6 has been identified as a cancer‐associated cell surface marker that is rarely expressed in healthy tissues. In testicular germ cell tumors (GCT), CLDN6 is particularly detectable in seminomas, embryonal carcinomas, and choriocarcinomas.
Jule Zwick, Margaretha A. Skowron, Gereon Poschmann, Patrick Petzsch, Ann Kathrin Bergmann, Kai Stühler, Jochen Hecht, Daniel Nettersheim   +7 more
wiley   +1 more source

MDM2 Inhibitor [PDF]

, 2020
openaire   +1 more source